Literature DB >> 11246869

Characterization of the mouse islet-specific glucose-6-phosphatase catalytic subunit-related protein gene promoter by in situ footprinting: correlation with fusion gene expression in the islet-derived betaTC-3 and hamster insulinoma tumor cell lines.

L J Bischof1, C C Martin, C A Svitek, B T Stadelmaier, L A Hornbuckle, J K Goldman, J K Oeser, J C Hutton, R M O'Brien.   

Abstract

Glucose-6-phosphatase (G6Pase) is a multicomponent system located in the endoplasmic reticulum comprising a catalytic subunit and transporters for glucose-6-phosphate, inorganic phosphate, and glucose. We have recently cloned a novel gene that encodes an islet-specific G6Pase catalytic subunit-related protein (IGRP) (Ebert et al., Diabetes 48:543-551, 1999). To begin to investigate the molecular basis for the islet-specific expression of the IGRP gene, a series of truncated IGRP-chloramphenicol acetyltransferase (CAT) fusion genes were transiently transfected into the islet-derived mouse betaTC-3 and hamster insulinoma tumor cell lines. In both cell lines, basal fusion gene expression decreased upon progressive deletion of the IGRP promoter sequence between -306 and -66, indicating that multiple promoter regions are required for maximal IGRP-CAT expression. The ligation-mediated polymerase chain reaction footprinting technique was then used to compare trans-acting factor binding to the IGRP promoter in situ in betaTC-3 cells, which express the endogenous IGRP gene, and adrenocortical Y1 cells, which do not. Multiple trans-acting factor binding sites were selectively identified in betaTC-3 cells that correlate with regions of the IGRP promoter identified as being required for basal IGRP-CAT fusion gene expression. The data suggest that hepatocyte nuclear factor 3 may be important for basal IGRP gene expression, as it is for glucagon, GLUT2, and Pdx-1 gene expression. In addition, binding sites for several trans-acting factors not previously associated with islet gene expression, as well as binding sites for potentially novel proteins, were identified.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11246869     DOI: 10.2337/diabetes.50.3.502

Source DB:  PubMed          Journal:  Diabetes        ISSN: 0012-1797            Impact factor:   9.461


  11 in total

1.  A pancreatic beta-cell-specific homolog of glucose-6-phosphatase emerges as a major target of cell-mediated autoimmunity in diabetes.

Authors:  John C Hutton; George S Eisenbarth
Journal:  Proc Natl Acad Sci U S A       Date:  2003-07-14       Impact factor: 11.205

2.  Association of connexin36 with zonula occludens-1 in HeLa cells, betaTC-3 cells, pancreas, and adrenal gland.

Authors:  Xinbo Li; Carl Olson; Shijun Lu; James I Nagy
Journal:  Histochem Cell Biol       Date:  2004-11-03       Impact factor: 4.304

3.  The pancreatic islet β-cell-enriched transcription factor Pdx-1 regulates Slc30a8 gene transcription through an intronic enhancer.

Authors:  Lynley D Pound; Yan Hang; Suparna A Sarkar; Yingda Wang; Laurel A Milam; James K Oeser; Richard L Printz; Catherine E Lee; Roland Stein; John C Hutton; Richard M O'Brien
Journal:  Biochem J       Date:  2011-01-01       Impact factor: 3.857

Review 4.  Glucose-6-phosphatase catalytic subunit gene family.

Authors:  John C Hutton; Richard M O'Brien
Journal:  J Biol Chem       Date:  2009-08-20       Impact factor: 5.157

5.  Upstream stimulatory factor (USF) and neurogenic differentiation/beta-cell E box transactivator 2 (NeuroD/BETA2) contribute to islet-specific glucose-6-phosphatase catalytic-subunit-related protein (IGRP) gene expression.

Authors:  Cyrus C Martin; Christina A Svitek; James K Oeser; Eva Henderson; Roland Stein; Richard M O'Brien
Journal:  Biochem J       Date:  2003-05-01       Impact factor: 3.857

6.  Multiple functional polymorphisms in the G6PC2 gene contribute to the association with higher fasting plasma glucose levels.

Authors:  D A Baerenwald; A Bonnefond; N Bouatia-Naji; B P Flemming; O C Umunakwe; J K Oeser; L D Pound; N L Conley; S Cauchi; S Lobbens; E Eury; B Balkau; O Lantieri; P K Dadi; D A Jacobson; P Froguel; R M O'Brien
Journal:  Diabetologia       Date:  2013-03-19       Impact factor: 10.122

7.  Foxa2 and MafA regulate islet-specific glucose-6-phosphatase catalytic subunit-related protein gene expression.

Authors:  Cyrus C Martin; Brian P Flemming; Yingda Wang; James K Oeser; Richard M O'Brien
Journal:  J Mol Endocrinol       Date:  2008-08-27       Impact factor: 5.098

8.  Characterization of the human SLC30A8 promoter and intronic enhancer.

Authors:  Lynley D Pound; Suparna A Sarkar; Stéphane Cauchi; Yingda Wang; James K Oeser; Catherine E Lee; Philippe Froguel; John C Hutton; Richard M O'Brien
Journal:  J Mol Endocrinol       Date:  2011-09-30       Impact factor: 5.098

9.  A single-nucleotide polymorphism in a methylatable Foxa2 binding site of the G6PC2 promoter is associated with insulin secretion in vivo and increased promoter activity in vitro.

Authors:  Christine Dos Santos; Pierre Bougnères; Delphine Fradin
Journal:  Diabetes       Date:  2008-11-04       Impact factor: 9.461

10.  PDX-1 is a therapeutic target for pancreatic cancer, insulinoma and islet neoplasia using a novel RNA interference platform.

Authors:  Shi-He Liu; Donald D Rao; John Nemunaitis; Neil Senzer; Guisheng Zhou; David Dawson; Marie-Claude Gingras; Zhaohui Wang; Richard Gibbs; Michael Norman; Nancy S Templeton; Francesco J Demayo; Bert O'Malley; Robbi Sanchez; William E Fisher; F Charles Brunicardi
Journal:  PLoS One       Date:  2012-08-08       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.